Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Novartis
Kivu Bioscience Inc.
City of Hope Medical Center
Bayer
University of California, Irvine
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
ViroMissile, Inc.
Dana-Farber Cancer Institute
AstraZeneca
Washington University School of Medicine
Essen Biotech
St. Jude Children's Research Hospital
MacroGenics
Alliance for Clinical Trials in Oncology
University of Nebraska
Adela, Inc
Perspective Therapeutics
Var2 Pharmaceuticals
UNICANCER
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Tanabe Pharma America, Inc.
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
British Columbia Cancer Agency
Washington University School of Medicine
Epkin
GONGCHU Biotechnology Co., Ltd
Lantheus Medical Imaging
Jonsson Comprehensive Cancer Center
Turning Point Therapeutics, Inc.
University of Pittsburgh
University of California, Irvine
Cancer Research UK
German Cancer Research Center
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Grupo Espanol de Investigacion en Sarcomas
Stanford University
Institut du Cancer de Montpellier - Val d'Aurelle
GI Innovation, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
Second Affiliated Hospital of Guangzhou Medical University